Skip to main content
Premium Trial:

Request an Annual Quote

Saladax, Bristol-Myers Squibb Expand Relationship

NEW YORK (GenomeWeb News) – Saladax today said it has expanded its relationship with Bristol-Myers Squibb and entered into a Master Early Development Collaboration Agreement.

As a result of the expansion, the companies may collaborate on multiple feasibility studies and companion diagnostic development projects, they said, adding they have already started a companion diagnostic project in an undisclosed field.

Financial terms of the deal were not disclosed.

Saladax and Bristol-Myers Squibb originally forged a collaboration in 2010 to develop companion diagnostic tests for Alzheimer's disease. That partnership was amended last year to include a commercial partner, Johnson & Johnson's Ortho Clinical Division.

"Building on our previous work together, which resulted in clinically valuable Alzheimer's disease assays, we're eager to continue marrying the scientific and clinical knowledge of Bristol-Myers Squibb and Saladax to improve the lives of patients in other clinical areas," Saladax President and CEO Kevin Harter said in a statement.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.